<DOC>
	<DOC>NCT02744755</DOC>
	<brief_summary>Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis</brief_summary>
	<brief_title>Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>The purpose of this study is to demonstrate similar efficacy and safety of GP2017 and US-licensed Humira® in patients with moderate to severe rheumatoid arthritis (RA) with inadequate response to Disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. Patients must have been diagnosed with RA ≥ 6 months prior to screening 2. Patients must have active disease, defined as DAS28CRP ≥ 3.2 at the time of screening 3. Patients must have CRP levels above 5mg/l or ESR levels above the upper limits of normal 4. Patients must have had inadequate clinical response to MTX 10 25 mg/week 1. Previous treatment with adalimumab, other antiTNFα therapies or cell depleting agents, e.g. antiCD20 therapy 2. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during treatment 3. Nursing (lactating) or pregnant women 4. History of or ongoing inflammatory or autoimmune diseases other than RA, e.g. mixed connective tissue disease, systemic lupus erythematosus etc. 5. Systemic corticosteroids &gt; 7.5mg/day within 4 weeks prior to baseline 6. History or presence of cancer or lymphoproliferative disease other than a successfully and completely treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix and/or removed noninvasive colon polyps, with no evidence of recurrence 7. History of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (New York Heart Association IIIIV), active peptic ulcer disease, recent stroke (within 3 months) 8. Subject known to have immune deficiency, history of positive human immunodeficiency virus (HIV) status or immunocompromised for other reasons 9. History of clinically significant hematologic (e.g. severe anemia, leucopenia, thrombocytopenia), renal or liver disease (e.g. glomerulonephritis, fibrosis, cirrhosis, hepatitis) 10. History of persistent chronic infection; recurrent infection or active infections 11. History of tuberculosis, presence of active tuberculosis, latent tuberculosis as detected by imaging (e.g. chest Xray, chest Computerized Tomography(CT) scan, Magnetic Resonance Imaging (MRI)) and/ or positive QuantiFERONTB Gold test (QFT) 12. History or evidence of opportunistic infections, e.g. histoplasmosis, listeriosis, legionellosis 13. Positive serology Hepatitis B (either HBsAg or antiHBc) or Hepatitis C (positive HCVAb or HCVRNA) indicative of previous or current infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>